Skip to main content
SpringerLink
Log in

Early Breast Cancer (Stage I and Stage II): Tailored Systemic Therapy for Endocrine-Resistant Breast Cancer

  • Chapter
Breast Cancer and Molecular Medicine

  • 1013 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. American Joint Committee on Cancer: “AJCC Cancer Staging Handbook.” New York: Springer-Verlag, 2002

    Google Scholar 

  2. Ravdin PM, Siminoff LA, Davis GJ et al.: Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. Journal of Clinical Oncology 2001: 19:980–991

    PubMed  CAS  Google Scholar 

  3. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. [see comment]. Lancet 1998: 351:1451–1467

    Article  Google Scholar 

  4. Polychemotherapy for early breast cancer: an overview of the randomized trials. Early Breast Cancer Trialists’ Collaborative Group. [see comment]. Lancet 1998: 352:930–942

    Google Scholar 

  5. Goldhirsch A, Wood WC, Gelber RD et al.: Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. [Review]. Journal of Clinical Oncology 2003: 21:3357–3365

    Article  PubMed  Google Scholar 

  6. National Institutes of Health Consensus Development Panel.: National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1–3, 2000. [Review]. Journal of the National Cancer Institute 2001: Monographs:5–15

    Google Scholar 

  7. International Breast Cancer Study Group.: Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. [see comment] [erratum appears in J Natl Cancer Inst 2002 Sep 4;94(17):1339]. Journal of the National Cancer Institute 2002: 94:1054–1065

    Google Scholar 

  8. Zambetti M, Valagussa P, Bonadonna G: Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-negative and estrogen receptor-negative breast cancer. Updated results. Annals of Oncology 1996: 7:481–485

    PubMed  CAS  Google Scholar 

  9. Mansour EG, Gray R, Shatila AH et al.: Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis—an intergroup study. Journal of Clinical Oncology 1998: 16:3486–3492

    PubMed  CAS  Google Scholar 

  10. Ravdin P, Olivotto I, Speers C et al. Should estrogen receptor negativity alone be an indication for chemotherapy in T1N0 breast cancer? Proc ASCO. Journal of Clinical Oncology 2003: 22:14

    Google Scholar 

  11. Wenger CR, Clark GM: S-phase fraction and breast cancer—a decade of experience. [Review]. Breast Cancer Research and Treatment 1998: 51:255–265

    Article  PubMed  CAS  Google Scholar 

  12. Hutchins L, Green S, Ravdin P et al. CMF versus CAF with and without tamoxifen in highrisk node-negative breast cancer and a natural history follow-up study in low-risk nodenegative patients: first results of intergroup trial 0102. Proc ASCO. Journal of Clinical Oncology 1998:17:1al

    Google Scholar 

  13. Jones S, Clark G, Koleszar G et al. Low proliferative rate of invasive nodenegative breast cancer predicts for a favorable outcome without adjuvant chemotherapy. Proc ASCO. Journal of Clinical Oncology 1999: 18:70a

    Google Scholar 

  14. Goldhirsch A, Glick JH, Gelber RD, Senn HJ: Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. [see comment]. [Review]. Journal of the National Cancer Institute 1998: 90:1601–1608

    Article  PubMed  CAS  Google Scholar 

  15. Daidone MG, Silvestrini R: Prognostic and predictive role of proliferation indices in adjuvant therapy of breast cancer. [Review] [90 refs]. Journal of the National Cancer Institute 2001: Monographs:27–35

    Google Scholar 

  16. Slamon DJ, Clark GM, Wong SG et al.: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987: 235:177–182

    Article  PubMed  CAS  Google Scholar 

  17. Ross JS, Fletcher JA, Linette GP et al.: The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. [Review]. Oncologist 2003: 8:307–325

    Article  PubMed  CAS  Google Scholar 

  18. Keyomarsi K, Tucker SL, Buchholz TA et al.: Cyclin E and survival in patients with breast cancer. [see comment] [erratum appears in N Engl J Med 2003 Jan 9;348(2):186]. New England Journal of Medicine 2002: 347:1566–1575

    Article  PubMed  CAS  Google Scholar 

  19. Porter PL, Malone KE, Heagerty PJ et al.: Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. [see comment]. Nature Medicine 1997: 3:222–225

    Article  PubMed  CAS  Google Scholar 

  20. Tan P, Cady B, Wanner M et al.: The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Research 1997: 57:1259–1263

    PubMed  CAS  Google Scholar 

  21. Catzavelos C, Bhattacharya N, Ung YC et al.: Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. [see comment]. Nature Medicine 1997: 3:227–230

    Article  PubMed  CAS  Google Scholar 

  22. Volpi A, De Paola F, Nanni O et al.: Prognostic significance of biologic markers in nodenegative breast cancer patients: a prospective study. Breast Cancer Research and Treatment 2000: 63:181–192

    Article  PubMed  CAS  Google Scholar 

  23. Barnes DM, Gillett CE: Cyclin D1 in breast cancer. [Review]. Breast Cancer Research and Treatment 1998: 52:1–15

    Article  PubMed  CAS  Google Scholar 

  24. Gruvberger S, Ringner M, Chen Y et al.: Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Research 2001: 61:5979–5984

    PubMed  CAS  Google Scholar 

  25. Janicke F, Prechtl A, Thomssen C et al.: Randomized adjuvant chemotherapy trial in highrisk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. Journal of the National Cancer Institute 2001: 93:913–920

    Article  PubMed  CAS  Google Scholar 

  26. Look MP, van Putten WL, Duffy MJ et al.: Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. Journal of the National Cancer Institute 2002: 94:116–128

    PubMed  CAS  Google Scholar 

  27. Goldhirsch A, Glick JH, Gelber RD et al.: Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. [see comment]. [Review]. Journal of Clinical Oncology 2001: 19:3817–3827

    PubMed  CAS  Google Scholar 

  28. van de Vijver MJ, He YD, van’t Veer LJ et al.: A gene-expression signature as a predictor of survival in breast cancer. see comment]. New England Journal of Medicine 2002: 347:1999–2009

    Article  PubMed  Google Scholar 

  29. Perou CM, Sorlie T, Eisen MB et al.: Molecular portraits of human breast tumours. Nature 2000: 406:747–752

    Article  PubMed  CAS  Google Scholar 

  30. Foulkes WD, Stefansson IM, Chappuis PO et al.: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. Journal of the National Cancer Institute 2003: 95:1482–1485

    PubMed  CAS  Google Scholar 

  31. Fisher B, Brown AM, Dimitrov NV et al.: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. Journal of Clinical Oncology 1990: 8:1483–1496

    PubMed  CAS  Google Scholar 

  32. Jones S, Savin M, Asmar L et al. Three year results of a prospective randomized trial of adjuvant chemotherapy for patients with stage I-III operable, invasive breast cancer comparing four courses of doxorubicin/cyclophosphamide to four courses of docetaxel/cyclophosphamide. Proc ASCO. Journal of Clinical Oncology 2003: 22:15

    Article  CAS  Google Scholar 

  33. Bonadonna G, Valagussa P, Moliterni A et al.: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. [see comment]. New England Journal of Medicine 1995: 332:901–906

    Article  PubMed  CAS  Google Scholar 

  34. Martin M, Pienkowski T, Mackey J et al. TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001: 55 months follow-up. Proc San Antonio Breast Cancer Symposium. Breast Cancer Research and Treatment 2003: 82

    Google Scholar 

  35. Citron ML, Berry DA, Cirrincione C et al.: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. [see comment] [erratum appears in Journal of Clinical Oncology 2003 Jun 1;21(11):2226]. Journal of Clinical Oncology 2003: 21:1431–1439

    Article  PubMed  CAS  Google Scholar 

  36. Levine MN, Bramwell VH, Pritchard KI et al.: Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. [see comment]. Journal of Clinical Oncology 1998: 16:2651–2658

    PubMed  CAS  Google Scholar 

  37. French Adjuvant Study Group.: Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. [see comment]. Journal of Clinical Oncology 2001: 19:602–611

    Google Scholar 

  38. Wood WC, Budman DR, Korzun AH et al.: Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. see comment] [erratum appears in N Engl J Med 1994 Jul 14;331(2):139]. New England Journal of Medicine 1994: 330:1253–1259

    Article  PubMed  CAS  Google Scholar 

  39. Bontenbal M, Andersson M, Wildiers J et al.: Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group. British Journal of Cancer 1998: 77:2257–2263

    PubMed  CAS  Google Scholar 

  40. Hortobagyi GN, Yap HY, Kau SW et al.: A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer. American Journal of Clinical Oncology 1989: 12:57–62

    PubMed  CAS  Google Scholar 

  41. Perez DJ, Harvey VJ, Robinson BA et al.: A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer. Journal of Clinical Oncology 1991: 9:2148–2152

    PubMed  CAS  Google Scholar 

  42. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group. Journal of Clinical Oncology 1988: 6:679–688

    Google Scholar 

  43. Valero V, Jones SE, Von Hoff DD et al.: A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. Journal of Clinical Oncology 1998: 16:3362–3368

    PubMed  CAS  Google Scholar 

  44. Jones S, Erban J, Overmoyer B et al. Randomized trial comparing docetaxel and paclitaxel in patients with metastatic breast cancer. Proc San Antonio Breast Cancer Symposium. Breast Cancer Research and Treatment 2003: 82:S9

    Google Scholar 

  45. Muss HB, Thor AD, Berry DA et al.: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. [see comment] [erratum appears in N Engl J Med 1994 Jul 21;331(3):211]. New England Journal of Medicine 1994: 330:1260–1266

    Article  PubMed  CAS  Google Scholar 

  46. Thor AD, Berry DA, Budman DR et al.: erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. [see comment]. Journal of the National Cancer Institute 1998: 90:1346–1360

    Article  PubMed  CAS  Google Scholar 

  47. Paik S, Bryant J, Tan-Chiu E et al.: HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. Journal of the National Cancer Institute 2000: 92:1991–1998

    Article  PubMed  CAS  Google Scholar 

  48. Paik S, Bryant J, Park C et al.: erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. [see comment]. Journal of the National Cancer Institute 1998: 90:1361–1370

    Article  PubMed  CAS  Google Scholar 

  49. Di Leo A, Gancberg D, Larsimont D et al.: HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clinical Cancer Research 2002: 8:1107–1116

    PubMed  Google Scholar 

  50. Di Leo A, Larsimont D, Gancberg D et al.: HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Annals of Oncology 2001: 12:1081–1089

    Article  PubMed  Google Scholar 

  51. Gancberg D, Jarvinen T, Di Leo A et al.: Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2/NEU testing. Breast Cancer Research and Treatment 2002: 74:113–120

    Article  PubMed  CAS  Google Scholar 

  52. Jarvinen TA, Tanner M, Barlund M et al.: Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes, Chromosomes and Cancer 1999: 26:142–150

    Article  CAS  Google Scholar 

  53. Jarvinen TA, Tanner M, Rantanen V et al.: Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. American Journal of Pathology 2000: 156:839–847

    PubMed  CAS  Google Scholar 

  54. Pestalozzi BC, Peterson HF, Gelber RD et al.: Prognostic importance of thymidylate synthase expression in early breast cancer. Journal of Clinical Oncology 1997: 15:1923–1931

    PubMed  CAS  Google Scholar 

  55. Romain S, Spyratos F, Descotes F et al.: Prognostic of DNA-synthesizing enzyme activities (thymidine kinase and thymidylate synthase) in 908 T1-T2, N0-N1, M0 breast cancers: a retrospective multicenter study. International Journal of Cancer 2000: 87:860–868

    Article  CAS  Google Scholar 

  56. Foekens JA, Romain S, Look MP et al.: Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy. Cancer Research 2001: 61:1421–1425

    PubMed  CAS  Google Scholar 

  57. Bernard-Marty C, Treilleux I, Dumontet C et al.: Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study. Clinical Breast Cancer 2002: 3:341–345

    Article  PubMed  CAS  Google Scholar 

  58. Monzo M, Rosell R, Sanchez JJ et al.: Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. Journal of Clinical Oncology 1999: 17:1786–1793

    PubMed  CAS  Google Scholar 

  59. Giannakakou P, Sackett DL, Kang YK et al.: Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. Journal of Biological Chemistry 1997: 272:17118–17125

    Article  PubMed  CAS  Google Scholar 

  60. Maeno K, Ito K, Hama Y et al.: Mutation of the class I beta-tubulin gene does not predict response to paclitaxel for breast cancer. Cancer Letters 2003: 198:89–97

    Article  PubMed  CAS  Google Scholar 

  61. O’Shaughnessy J, Miles D, Vukelja S et al.: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. Journal of Clinical Oncology 2002: 20:2812–2823

    Article  PubMed  CAS  Google Scholar 

  62. Valagussa P, Moliterni A, Terenziani M et al.: Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancer. [see comment]. Annals of Oncology 1994: 5:803–808

    PubMed  CAS  Google Scholar 

  63. Zambetti M, Moliterni A, Materazzo C et al.: Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. Journal of Clinical Oncology 2001: 19:37–43

    PubMed  CAS  Google Scholar 

  64. Piccart MJ, Di Leo A, Beauduin M et al.: Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. Journal of Clinical Oncology 2001: 19:3103–3110

    PubMed  CAS  Google Scholar 

  65. Crump M, Tu D, Shepherd L et al.: Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology 2003: 21:3066–3071

    Article  PubMed  CAS  Google Scholar 

  66. Smith RE, Bryant J, DeCillis A et al.: Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. Journal of Clinical Oncology 2003: 21:1195–1204

    Article  PubMed  CAS  Google Scholar 

  67. Fisher B, Anderson S, Wickerham DL et al.: Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. Journal of Clinical Oncology 1997: 15:1858–1869

    PubMed  CAS  Google Scholar 

  68. Nabholtz J, Pienkowski T, Mackey J et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer patients: interim analysis of the BCIRG 001. Proc ASCO. Journal of Clinical Oncology 2002: 21:36a

    Google Scholar 

  69. Therasse P, Mauriac L, Welnicka-Jaskiewicz M et al.: Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. [Review] [33 refs]. Journal of Clinical Oncology 2003: 21:843–850

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Level 6, Gloucester House, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW, 2050, Australia

    Anne L. Hamilton

Authors
  1. Anne L. Hamilton
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Dept. of Medical Oncology, Jules Bordet Institute, Boulevard de Waterloo, 215, 1000, Brussels, Belgium

    Martine J. Piccart MD, PhD  & Fatima Cardoso MD  & 

  2. Anderson Cancer Center, The University of Texas MD, 1515 Holcombe Blvd, Houston, TX, 77030-4095, USA

    Mien-Chie Hung PhD

  3. Dept. of Radiation Oncology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, Pennsylvania, 19104-4283, USA

    Lawrence J. Solin MD

  4. Dept. of Surgery, Emory University Hospital, 1364 Clifton Road NE B206, Atlanta, Georgia, 30322-1059, USA

    William C. Wood MD

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Hamilton, A.L. (2006). Early Breast Cancer (Stage I and Stage II): Tailored Systemic Therapy for Endocrine-Resistant Breast Cancer. In: Piccart, M.J., Hung, MC., Solin, L.J., Cardoso, F., Wood, W.C. (eds) Breast Cancer and Molecular Medicine. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-28266-2_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-28266-2_16

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-28265-5

  • Online ISBN: 978-3-540-28266-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation